Rodman & Renshaw downgrades BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) from 'Market Outperform / Speculative Risk to Market Perform / Speculative ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE